Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

被引：26

作者：

Jethava, Y. ^{[1
]}

Mitchell, A. ^{[2
]}

Zangari, M. ^{[1
]}

Waheed, S. ^{[1
]}

Schinke, C. ^{[1
]}

Thanendrarajan, S. ^{[1
]}

Sawyer, J. ^{[1
]}

Alapat, D. ^{[1
]}

Tian, E. ^{[1
]}

Stein, C. ^{[1
]}

Khan, R. ^{[1
]}

Heuck, Cj ^{[1
]}

Petty, N. ^{[1
]}

Avery, D. ^{[1
]}

Steward, D. ^{[1
]}

Smith, R. ^{[1
]}

Bailey, C. ^{[1
]}

Epstein, J. ^{[1
]}

Yaccoby, S. ^{[1
]}

Hoering, A. ^{[2
]}

Crowley, J. ^{[2
]}

Morgan, G. ^{[1
]}

Barlogie, B. ^{[1
]}

van Rhee, F. ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA

[2] Canc Res & Biostat, Seattle, WA USA

来源：

BLOOD CANCER JOURNAL | 2016年 / 6卷

关键词：

INTERNATIONAL STAGING SYSTEM;

D O I：

10.1038/bcj.2016.64

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used and we reported that gene expression profile (GEP)-defined high risk was a major predictor of relapse. In spite of our best efforts, the majority of GEP70 high-risk patients relapse and we have noted higher relapse rates during drug-free intervals. This prompted us to explore the concept of less intense drug dosing with shorter intervals between courses with the aim of preventing inter-course relapse. Here we report the outcome of the Total Therapy 5 trial, where this concept was tested. This regimen effectively reduced early mortality and relapse but failed to improve progression-free survival and overall survival due to relapse early during maintenance.

引用

页码：e453 / e453

页数：4

共 16 条

[1] Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies [J].

Barlogie, B ;

Tricot, G ;

Rasmussen, E ;

Anaissie, E ;

van Rhee, F ;

Zangari, M ;

Fassas, A ;

Hollmig, K ;

Pineda-Roman, M ;

Shaughnessy, J ;

Epstein, J ;

Crowley, J .

BLOOD, 2006, 107 (07) :2633-2638

[2] Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].

Barlogie, Bart ;

Anaissie, Elias ;

van Rhee, Frits ;

Haessler, Jeffrey ;

Hollmig, Klaus ;

Pineda-Roman, Mauricio ;

Cottler-Fox, Michele ;

Mohiuddin, Abid ;

Alsayed, Yazan ;

Tricot, Guido ;

Bolejack, Vanessa ;

Zangari, Maurizio ;

Epstein, Joshua ;

Petty, Nathan ;

Steward, Douglas ;

Jenkins, Bonnie ;

Gurley, Jennifer ;

Sullivan, Ellen ;

Crowley, John ;

Shaughnessy, John D. Jr .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185

[3] Curing myeloma at last: defining criteria and providing the evidence [J].

Barlogie, Bart ;

Mitchell, Alan ;

van Rhee, Frits ;

Epstein, Joshua ;

Morgan, Gareth J. ;

Crowley, John .

BLOOD, 2014, 124 (20) :3043-3051

[4] Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome [J].

Dickens, Nicholas J. ;

Walker, Brian A. ;

Leone, Paola E. ;

Johnson, David C. ;

Brito, Jose L. ;

Zeisig, Athanasia ;

Jenner, Matthew W. ;

Boyd, Kevin D. ;

Gonzalez, David ;

Gregory, Walter M. ;

Ross, Fiona M. ;

Davies, Faith E. ;

Morgan, Gareth J. .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1856-1864

[5] Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group [J].

Fernandez de Larrea, C. ;

Kyle, R. A. ;

Durie, B. G. M. ;

Ludwig, H. ;

Usmani, S. ;

Vesole, D. H. ;

Hajek, R. ;

San Miguel, J. F. ;

Sezer, O. ;

Sonneveld, P. ;

Kumar, S. K. ;

Mahindra, A. ;

Comenzo, R. ;

Palumbo, A. ;

Mazumber, A. ;

Anderson, K. C. ;

Richardson, P. G. ;

Badros, A. Z. ;

Caers, J. ;

Cavo, M. ;

Leleu, X. ;

Dimopoulos, M. A. ;

Chim, C. S. ;

Schots, R. ;

Noeul, A. ;

Fantl, D. ;

Mellqvist, U-H ;

Landgren, O. ;

Chanan-Khan, A. ;

Moreau, P. ;

Fonseca, R. ;

Merlini, G. ;

Lahuerta, J. J. ;

Blade, J. ;

Orlowski, R. Z. ;

Shah, J. J. .

LEUKEMIA, 2013, 27 (04) :780-791

[6]

Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876

[7] Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma [J].

Garfall, Alfred L. ;

Maus, Marcela V. ;

Hwang, Wei-Ting ;

Lacey, Simon F. ;

Mahnke, Yolanda D. ;

Melenhorst, J. Joseph ;

Zheng, Zhaohui ;

Vogl, Dan T. ;

Cohen, Adam D. ;

Weiss, Brendan M. ;

Dengel, Karen ;

Kerr, Naseem D. S. ;

Bagg, Adam ;

Levine, Bruce L. ;

June, Carl H. ;

Stadtmauer, Edward A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (11) :1040-1047

[8] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[9] Inhibiting MEK in MAPK pathway-activated myeloma [J].

Heuck, C. J. ;

Jethava, Y. ;

Khan, R. ;

van Rhee, F. ;

Zangari, M. ;

Chavan, S. ;

Robbins, K. ;

Miller, S. E. ;

Matin, A. ;

Mohan, M. ;

Ali, S. M. ;

Stephens, P. J. ;

Ross, J. S. ;

Miller, V. A. ;

Davies, F. ;

Barlogie, B. ;

Morgan, G. .

LEUKEMIA, 2016, 30 (04) :976-980

[10] Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 [J].

Mikhael, Joseph R. ;

Dingli, David ;

Roy, Vivek ;

Reeder, Craig B. ;

Buadi, Francis K. ;

Hayman, Suzanne R. ;

Dispenzieri, Angela ;

Fonseca, Rafael ;

Sher, Taimur ;

Kyle, Robert A. ;

Lin, Yi ;

Russell, Stephen J. ;

Kumar, Shaji ;

Bergsagel, P. Leif ;

Zeldenrust, Steven R. ;

Leung, Nelson ;

Drake, Matthew T. ;

Kapoor, Prashant ;

Ansell, Stephen M. ;

Witzig, Thomas E. ;

Lust, John A. ;

Dalton, Robert J. ;

Gertz, Morie A. ;

Stewart, Keith ;

Rajkumar, S. Vincent ;

Chanan-Khan, Asher ;

Lacy, Martha Q. .

MAYO CLINIC PROCEEDINGS, 2013, 88 (04) :360-376

← 1 2 →